Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho ( D ) immune globulin intravenous administration for immune thrombocytopenic purpura

@inproceedings{Gaines1995DisseminatedIC,
  title={Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho ( D ) immune globulin intravenous administration for immune thrombocytopenic purpura},
  author={Ann Reed Gaines},
  year={1995}
}
The Food and Drug Administration (FDA) licensed Rho(D) immune globulin intravenous (anti-D IGIV) on March 24, 1995, for treatment of immune thrombocytopenic purpura (ITP). A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP or secondary thrombocytopenia. Eleven of those patients also experienced clinically compromising anemia, transfusion with packed red blood cells, renal insufficiency, dialysis, or… CONTINUE READING
8 Citations
1 References
Similar Papers

Similar Papers

Loading similar papers…